Immunology and Biotherapies
37.8K views | +2 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
Scoop.it!

ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) specific neutralizes IL-1α and IL-1β

ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) specific neutralizes IL-1α and IL-1β | Immunology and Biotherapies | Scoop.it
(2015). Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) molecule that specifically and potently neutralizes both IL-1α and IL-1β. mAbs: Vol. 7, No. 3, pp. 605-619. doi: 10.1080/19420862.2015.1026501

Via Krishan Maggon
Krishan Maggon 's curator insight, June 15, 2015 3:40 AM

mAbs  Vol & Issue 3

 

Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-IgTM) molecule that specifically and potently neutralizes both IL-1α and IL-1β View full textDownload full textSupplementalOpen accessDOI:10.1080/19420862.2015.1026501Susan E Lacya*, Chengbin Wub, Dominic J Ambrosic, Chung-Ming Hsieha, Sahana Bosea, Renee Millera, Donna M Conlond, Edit Tarcsae, Ravi Charif, Tariq Ghayurc & Rajesh V Kamathg

pages 605-619

Publishing models and article dates explainedReceived: 11 Nov 2014Accepted: 1 Mar 2015Accepted author version posted online: 12 Mar 2015
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies
Scoop.it!

Humira (adalimumab, AbbVie) remains the top selling human medicinal brand and mab in 2014

Humira (adalimumab, AbbVie) remains the top selling human medicinal brand and mab in 2014 | Immunology and Biotherapies | Scoop.it

REPORTS FULL-YEAR ADJUSTED EPS OF $3.32, UP 5.7 PERCENT; GAAP EPS $1.10- DELIVERS FOURTH-QUARTER ADJUSTED REVENUE OF $5.371 BILLION, UP 8.9 PERCENT OVER FOURTH-QUARTER 2013 (UP 5.1 PERCENT ON A REPORTED BASIS); GAAP REVENUE $5.452 BILLION- REVENUE GROWTH IN THE QUARTER REFLECTS 14.4 PERCENT GLOBAL OPERATIONAL SALES GROWTH FROM HUMIRA (UP 10.6 PERCENT ON A REPORTED BASIS) AND STRONG GROWTH FROM OTHER KEY PRODUCTS- DELIVERS ADJUSTED GROSS MARGIN IMPROVEMENT OF 410 BASIS POINTS IN THE FOURTH QUARTER- REPORTS FOURTH-QUARTER ADJUSTED EPS OF $0.89, UP 8.5 PERCENT; GAAP EPS ($0.51)- LAUNCHES INTERFERON-FREE HCV REGIMEN FOLLOWING APPROVAL IN UNITED STATES, EUROPE AND CANADA- CONFIRMS 2015 ADJUSTED EPS GUIDANCE RANGE, REFLECTING INDUSTRY-LEADING GROWTH VERSUS THE PRIOR YEAR

 

 Global HUMIRA sales increased 10.6 percent, or 14.4 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations.  


Via Krishan Maggon
Krishan Maggon 's curator insight, February 4, 2015 5:07 AM

Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.  

 

Remicade

Rituxan

Avastin

Herceptin    

 

are the other 5 top selling mabs in 2014.

 

to be updated

Krishan Maggon 's curator insight, February 4, 2015 5:10 AM

Humira with 2014 sales of $12.5 billion retains the top selling human medicine for the second year after the patent expiry of Lipitor.  

 

Sovaldi

Remicade

Enbrel

Rituxan

Avastin

Herceptin

   

 

are the other top selling medicines in 2014.

 

to be updated